<DOC>
	<DOCNO>NCT00002022</DOCNO>
	<brief_summary>The objective Eprex ( erythropoietin ) Treatment Program provide erythropoietin treatment anemia AIDS patient .</brief_summary>
	<brief_title>Treatment Program Anemia AIDS Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : Patients follow exclude : Life expectancy &lt; 3 month . = &lt; grade 4 performance score . AIDSrelated dementia . Uncontrolled hypertension . Acute symptomatic opportunistic infection AIDSdefining illness . Patients follow exclude : Life expectancy &lt; 3 month . = &lt; grade 4 performance score . AIDSrelated dementia . Uncontrolled hypertension . Acute symptomatic opportunistic infection AIDSdefining illness . Patients must : A clinical diagnosis AIDS . Hematocrit &lt; 30 percent . Endogenous serum erythropoietin level = &lt; 500 U/ml . A life expectancy = &gt; 3 month . &gt; Grade 4 performance score .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1991</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Anemia</keyword>
	<keyword>Zidovudine</keyword>
</DOC>